Leqembi seeks full approval, while Takeda hopes for a dengue green light and Verrica looks to break its streak of bad luck.
And conveniently, Celltrans blazes a trail for cell therapies in diabetes.
After a hiatus Nkarta comes back with a new lymphodepletion regimen to boost its lead Car-NK therapy.
But it still has a long way to go with its islet cell therapies.
The private group celebrates a double first for its mRNA-generated Car-T therapy in myasthenia gravis.
Despite showing arguable signals of efficacy Uniqure’s Huntington’s disease gene therapy has some fundamental problems.